Gold prices ended the week down 1.7% at $4,354.90 an ounce as investors brace for a likely Federal Reserve rate hike next week, with markets pricing in nearly a 90% chance. Despite inflation remaining above the Fed's 2% target, rising U.S. government debt and high bond yields are limiting the Fed's ability to aggressively raise rates. Analysts suggest gold's support above $4,300 reflects doubts about the Fed's rate hike impact and growing concerns over sovereign debt risks. Upcoming central bank decisions and economic data releases will continue to influence gold's price trajectory.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...
